Mayo Clinic

抗衰老药物在临床前研究中减少COVID-19症状。

妙佑医疗国际(Mayo Clinic)的研究人员和明尼苏达大学的同事表明,COVID-19(2019冠状病毒病)加剧了体内衰老细胞的破坏性影响。在临床前研究中,妙佑医疗国际研发的抗衰老药物显著降低了老年实验鼠因COVID(冠状病毒病)感染引起的炎症、疾病和死亡率。该研究结果已发表在《科学》期刊中。

 

衰老细胞(在体内持续存在的受损或无功能性细胞)会导致各种老化和疾病,包括炎症和多种慢性疾病。基于妙佑医疗国际提出的衰老细胞“放大器/变阻器假设”,研究人员尝试发现COVID-19如何在老年人和慢性疾病患者中引发更高的死亡率。他们表明,人类衰老细胞会放大对严重急性呼吸道综合征(SARS)刺突蛋白的反应,而激发形成更多由衰老细胞引发的炎症和组织损伤的诱导因子。

 

研究人员还发现,使用明尼苏达大学研发的模型于感染病毒(包括与SARS-CoV-2相关的冠状病毒)的老年实验鼠,有表现出扩大反应性的衰老细胞增加、发炎症状,并且死亡率接近100%。当研究人员在感染之前或之后用抗衰老药物(选择性去除体内衰老细胞的药物)治疗类似的实验鼠时,结果恰恰相反。抗病毒抗体增加,而炎症和衰老细胞出现的迹象以及死亡率则显著减少,因此受感染的老年实验鼠的存活率更加接近年轻的实验鼠。

 

研究人员建议,减轻老年或慢性疾病患者衰老细胞的现有负担可能会提升他们的恢复力,并降低他们死于病毒感染(包括SARS-CoV-2)的风险。目前正在开展三项此类临床试验。

 

“尽管疫苗的使用在不断增加,抗衰老药物仍然可以帮助无法接种疫苗的患者,特别是对疗养院中患有合并症或免疫问题的老年患者,”Kogod Center on Aging主任James Kirkland医学博士和妙佑医疗国际本研究的资深作者Tamar Tchkonia博士共同说道。该研究表明,抗衰老药物还可能改善老年患者对疫苗的反应,同时帮助他们对抗细菌和其他病毒感染。

 

该研究得到了如下机构的支持:美国国立卫生研究院、康纳基金会、Robert J.和Theresa W. Ryan、Robert P.和Arlene R. Kogod、诺伯基金会、明尼苏达大学临床与转化科学研究所、衰老生物学医学发现团队,以及艾琳钻石基金会/美国老化研究联合会博士后转型10奖项。此外,该研究还获得了Fesler-Lampert老化研究主席奖和AFAR青年教员奖。

 

###

 

关于妙佑医疗国际(Mayo Clinic)

 

妙佑医疗国际是一所致力于创新并集临床实践、医学教育和科学研究为一体的非营利机构,以恻隐之心竭诚提供精湛医术和解决方案给需要治疗的每个人请访问妙佑医疗国际新闻网,取得更多妙佑医疗国际的新闻信息关于COVID-19的详情,包括妙佑医疗国际的冠状病毒分布图追踪工具含有的14天COVID-19趋势预报,请访问妙佑医疗国际COVID-19资源中心。

 

 

媒体联系: 

请联系妙佑医疗国际公共事务部:Bob Nellis。邮箱:[email protected] 



Filters close

Showing results

110 of 5872
Released: 24-Jun-2021 4:55 PM EDT
Virus that causes COVID-19 can find alternate route to infect cells
Washington University in St. Louis

The virus that causes COVID-19 normally gets inside cells by attaching to a protein called ACE2. Researchers at Washington University School of Medicine in St. Louis have found that a single mutation confers the ability to enter cells through another route, which may threaten the effectiveness of COVID-19 vaccines and therapeutics designed to block the standard route of entry.

Newswise: Is it a Virus or Bacteria? New Tech Rapidly Tests for COVID-19 and More
Released: 24-Jun-2021 3:05 PM EDT
Is it a Virus or Bacteria? New Tech Rapidly Tests for COVID-19 and More
Homeland Security's Science And Technology Directorate

S&T is preparing for future outbreaks/pandemics by investing in a new tech that can quickly discriminate between bacterial and viral infections so that the U.S. can triage patients and plan a response without delay.

Released: 24-Jun-2021 12:30 PM EDT
A tecnologia de IA e ECG pode descartar rapidamente a infecção por COVID-19, concluiu o estudo da Mayo Clinic
Mayo Clinic

A inteligência artificial (IA) pode oferecer uma maneira de determinar com precisão se uma pessoa não está infectada com a COVID-19. Um estudo retrospectivo internacional descobriu que a infecção pelo SARS-CoV-2, o vírus que causa a COVID-19, cria mudanças elétricas sutis no coração. Um eletrocardiograma (ECG) habilitado com IA pode detectar essas alterações e, potencialmente, ser usado como um teste de triagem rápido e confiável para descartar a infecção por COVID-19.

Released: 24-Jun-2021 12:10 PM EDT
妙佑医疗国际(Mayo Clinic)的研究发现,AI赋能的心电图技术有可能迅速排除COVID-19感染
Mayo Clinic

AI (人工智能)有可能提供准确判断一个人未感染COVID-19(2019冠状病毒病)的方法。一项国际回顾性研究发现,如果感染了导致COVID-19的SARS-CoV-2病毒,患者的心脏会产生微妙的电学变化。AI赋能的心电图(EKG)可以检测到这些变化,并有望被用于进行快速、可靠的COVID-19筛查检测,以排除COVID-19感染。

Newswise: 200421_Felgner_3205_sz-2-768x496.jpg
Released: 24-Jun-2021 11:50 AM EDT
UCI Professor Wins Spain’s Prestigious Princess of Asturias Award for Scientific Research
University of California, Irvine

Irvine, Calif., June 24, 2021 — Philip Felgner, Ph.D., professor in residence of physiology & biophysics at the University of California, Irvine, is one of seven scholars worldwide to win Spain’s prestigious Princess of Asturias Award for Technical and Scientific Research in recognition of their contributions to designing COVID-19 vaccines.

Released: 24-Jun-2021 11:00 AM EDT
New protein engineering method could accelerate the discovery of COVID-19 therapeutics
University of Michigan

Discovering and engineering nanobodies with properties suitable for treating human diseases ranging from cancer to COVID-19 is a time-consuming, laborious process.

Newswise: Decoding humans’ survival from coronaviruses
Released: 24-Jun-2021 11:00 AM EDT
Decoding humans’ survival from coronaviruses
University of Adelaide

An international team of researchers co-led by the University of Adelaide and the University of Arizona has analysed the genomes of more than 2,500 modern humans from 26 worldwide populations, to better understand how humans have adapted to historical coronavirus outbreaks.

access_time Embargo lifts in 2 days
Embargo will expire: 29-Jun-2021 4:00 PM EDT Released to reporters: 24-Jun-2021 10:35 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 29-Jun-2021 4:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: COVIDLockdownSimulations.jpg
Released: 24-Jun-2021 10:00 AM EDT
Pandemic Air Quality Affected By Weather, Not Just Lockdowns
Washington University in St. Louis

Using a diverse set of tools, the lab of Randall Martin shows how the pandemic did – or didn’t – affect levels of particulate matter during COVID lockdowns.

Released: 24-Jun-2021 6:05 AM EDT
Longest known SARS-CoV-2 infection of nearly 300 days successfully treated with new therapy
University of Bristol

An immunocompromised individual with the longest known PCR confirmed case of SARS-CoV-2 infection, lasting more than 290 days, has been successfully treated with two investigational monoclonal antibodies (laboratory engineered antibodies). Clinicians and researchers from the University of Bristol and North Bristol NHS Trust (NBT) worked closely to assess and treat the infection and want to highlight the urgent need for improved access to treatments for such people with persistent SARS-CoV-2 infection.


Showing results

110 of 5872

close
1.46096